Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2024 09:05 ET | Source: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
October 01, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
September 23, 2024 07:30 ET | Source: BioAtla, Inc.

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and...
September 16, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin’s activity in a high unmet need SCCHN patient...
September 09, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 28, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 08, 2024 16:05 ET | Source: BioAtla, Inc.

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H...
August 01, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
July 25, 2024 17:39 ET | Source: BioAtla, Inc.

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly...
July 23, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in...